Help Your Eligible* Patients Save on ZIRGAN
With the Bausch + Lomb Copay Program, most eligible* patients can save on their ZIRGAN prescriptions.
Most eligible* uninsured patients or not covered patients may pay as little as $79.
Patients can download and activate a Bausch + Lomb Copay Card by visiting bauschcopayprogram.com.
Once the card has been downloaded or activated, patients can take it to a participating independent pharmacy to pick up their prescription.
Patients who receive a physical copay card in office can activate online at bap.blsavingscard.com, on the phone by calling
1-877-494-4372, or by texting BLSAVINGS to 24109.†
Most eligible patients may pay as little as $79‡ on each prescription. If your Medicare prescription drug insurance does not cover your prescription, or if your out-of-pocket costs exceed $79‡ under that coverage, Bausch + Lomb may be able to help. Please visit blpartdcoupon.com to learn more.
*Offer not valid for patients whose prescriptions are reimbursed by any federal or state healthcare program, including Medicaid, Medicare, TRICARE, or any other federal or state healthcare program. Other restrictions apply. See complete Eligibility Criteria and Terms and Conditions at bauschcopayprogram.com.
†Message frequency varies. Reply HELP for help or STOP to opt out. See our SMS terms of service at bap.blsavingscard.com/mobile-terms and privacy policy at bausch.com/privacy.
‡Terms, conditions, and limitations apply. Most eligible patients may pay as little as $79. See terms, conditions, and limitations at bapd.blsavingscard.com.
Interested in ZIRGAN samples?
Requesting samples is quick and easy through the Bausch Sample Vault.
Request samplesIndication
ZIRGAN® is an antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in adults and pediatric patients aged 2 years and older.
Important Safety Information
- ZIRGAN® is indicated for topical ophthalmic use only.
- Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN®.
- Do not allow the tip of the container to touch any surface, as this may contaminate the ointment.
- If pain develops or if redness, itching, or inflammation becomes aggravated, the patient should be advised to consult a physician.
- Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
- Safety and efficacy in pediatric patients below the age of 2 years have not been established.
Click here for full Prescribing Information for ZIRGAN®.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.1-800-FDA-1088.
Follow Bausch + Lomb:
Indication
ZIRGAN® (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).
Important Safety Information
- ZIRGAN® is indicated for topical ophthalmic use only.
- Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN®.
- Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
- Safety and efficacy in pediatric patients below the age of 2 years have not been established.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.1-800-FDA-1088.
Click here for full Prescribing Information for ZIRGAN®.
ZIRGAN® is a trademark of Laboratoires Théa Corporation used under license.
THIS WEBSITE IS INTENDED FOR U.S.
HEALTHCARE PROFESSIONALS ONLY.
Please choose an option below: